Skip to main content
OpenTrials

Clinical trial condition

Refractory Malignant Solid Neoplasm

Explore clinical trials studying Refractory Malignant Solid Neoplasm. Study availability and eligibility vary by location and protocol.

91 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Refractory Malignant Solid Neoplasm trial results

Active, Not Recruiting

FID-007 in Treating Participants With Advanced Solid Tumors

NCT03537690

Conditions
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Hoag Memorial Hospital Newport Beach, California, United States
View Trial Details
Active, Not Recruiting

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

NCT02535312

Conditions
Adenoma, Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, +18 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

NCT04294628

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +6 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • NYP/Weill Cornell Medical Center New York, United States
View Trial Details
Active, Not Recruiting

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +23 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 29 locations
View Trial Details

Related conditions